The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Pharmacodynamic evaluation of pCDC2 as the target engagement biomarker to assess activity of MK-1775 a Wee1 tyrosine kinase inhibitor.
Shelonitda Rose
Employment or Leadership Position - Merck; Merck Sharp & Dohme
Stock Ownership - Merck; Merck
Jonathan D. Cheng
Employment or Leadership Position - Merck Sharp & Dohme
Stock Ownership - Merck
Johnny Viscusi
Employment or Leadership Position - Merck
Stock Ownership - Merck
Robert Iannone
Employment or Leadership Position - Merck Sharp & Dohme
Stock Ownership - Merck
Research Funding - Merck
Jan HM Schellens
No relevant relationships to disclose
Suzanne Leijen
No relevant relationships to disclose
Geoffrey Shapiro
No relevant relationships to disclose
Anna C. Pavlick
No relevant relationships to disclose
Amit M. Oza
Consultant or Advisory Role - Merck
Honoraria - Merck
Research Funding - Merck
Lee S. Rosen
Research Funding - Merck
Alessandra Tosolini
No relevant relationships to disclose
Raymond Lam
Employment or Leadership Position - Merck
Stock Ownership - Merck
Tim Demuth
No relevant relationships to disclose